CytoMed Therapeutics Announced That Its Exclusively Licensed Induced Pluripotent Stem Cell-based Technology Has Been Granted A Patent By The China National Intellectual Property Administration
Portfolio Pulse from Benzinga Newsdesk
CytoMed Therapeutics has been granted a patent by the China National Intellectual Property Administration for its exclusively licensed Induced Pluripotent Stem Cell-based technology. The US-listed company GDTC is mentioned in the article.
September 25, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
GDTC is mentioned in the news about CytoMed Therapeutics' patent approval in China. The impact on GDTC is unclear based on the information provided.
The article mentions GDTC in relation to CytoMed Therapeutics' patent approval in China. However, the exact nature of GDTC's involvement or potential impact is not specified in the article.
CONFIDENCE 50
IMPORTANCE 50
RELEVANCE 50